Shruthi R¹, Niruby Rasendrakumar², Subashini S³ and Nidhi Sharma⁴*

¹MBBS Student, Saveetha Medical College SIMATS, Kuthambaakam, Chennai, Tamil Nadu, India
²Junior Resident, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences , Chennai
³MSc Clinical Embryology, ARC, Saveetha Medical College SIMATS, Kuthambaakam, Chennai, Tamil Nadu, India
⁴Department of Obstetrics and Gynecology, Saveetha Medical College SIMATS, Kuthambaakam, Chennai, Tamil Nadu, India

*Corresponding Author: Nidhi Sharma, Department of Obstetrics and Gynecology, Saveetha Medical College SIMATS, Kuthambaakam, Chennai, Tamil Nadu, India.

Received: June 26, 2021; Published: August 18, 2021

Citation: Nidhi Sharma., et al. “Fetomaternal Outcome in Pregnancy with COVID-19". Acta Scientific Microbiology 5.9 (2021): 89-94.

Abstract

Aims and Objectives: This study was to done to find the feto-maternal outcome when universal screening for COVID -19 was done in pregnancy. The effects of COVID-19 on placental histology and any evidence of vertical transplacental transmission were also investigated.

Materials and Methods: A total of 850 pregnant women were screened from April 2020-July 2020 Eighty nine mothers were found positive for covid-19 with RTPCR. All pregnancies with covid 19 positive screen were admitted. 30 women were referred to labour room for intrapartum care and their feto maternal outcome was studied.

Results: Covid -19 pregnancy is associated with miscarriages, preterm labour and intrauterine deaths. Placental lesions commonly observed are perivillous fibinous exudates, microthrombi and microinfracts. All newborns were covid negative tested by RT-PCR and hence transplacental transfer is not recorded in this preliminary report.

Conclusion: The placenta acts as a barrier against transmission of COVID -19, though placental affection with microthrombi, infarcts and perivillous fibrosis were evident in almost all placenta in Pregnancy with Covid -19.

Keywords: Covid-19; Pregnancy; Fetus; Newborn; Placenta

Bibliography

1. WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) (2005).
2. Kwon JY., et al. “New insights into the relationship between viral infection and pregnancy complications”. American Journal of Reproductive Immunology 5 (2014): 387-390.
3. Brosnihan KB., et al. “Enhanced expression of Ang- (1-7) during pregnancy”. Brazilian Journal of Medical and Biological Research 8 (2004): 1255-1262.
4. Jamieson DJ., et al. “What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention”. Obstetrics and Gynecology5 (2014): 1005-1010.
5. Fisk NM and Atun R. “Systematic analysis of research underfunding in maternal and perinatal health”. BJOG 3 (2009): 347-356.
6. Hui DS. “Epidemic and emerging coronaviruses (severe acute respiratory syndrome and Middle East respiratory syndrome)”. Clinics in Chest Medicine 1 (2017): 71-86.
7. Song Z., et al. “From SARS to MERS, thrusting coronaviruses into the spotlight”. Viruses 1 (2019): 59.
8. Cui J., et al. “Origin and evolution of pathogenic coronaviruses”. Nature Reviews Microbiology (2019).
9. Zhou Y., et al. “Prospects for a MERS-CoV spike vaccine”. Expert Review on Vaccines8 (2018): 677-686
10. Su S., et al. “Epidemiology, genetic recombination, and pathogenesis of coronaviruses”. Trends in Microbiology 6 (2016): 490-502.
11. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 10224 (2020): 565-574.
12. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.

Copyright: © 2021 Nidhi Sharma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.